Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
31-45 of 231
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiersIs Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiersFriedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
BCMA mRNA CAR-T Shows Durable Benefit in MG
NeuroFrontiersBCMA mRNA CAR-T Shows Durable Benefit in MG
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
NeuroFrontiersOmaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
FA hiPSCs in Translational Drug Development
NeuroFrontiersFA hiPSCs in Translational Drug Development
Emerging Serum microRNAs as Early Signals in MS
NeuroFrontiersEmerging Serum microRNAs as Early Signals in MS
- advertisement
Advancing Pediatric MS Care: Insights from AAN 2026
NeuroFrontiersAdvancing Pediatric MS Care: Insights from AAN 2026
Elizabeth Wilson, MD
Strengthening Global Infrastructure for FSHD Trials
AudioAbstractsStrengthening Global Infrastructure for FSHD Trials
Marlene Mimi Maeusli, PhD.
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiersSpinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiersEarly ALS Patients Show Slowed Decline with Pridopidine Treatment
Christopher Lock, MD
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiersThe Burden of Cognitive Dysfunction in Multiple Sclerosis
Christopher Lock, MD
- advertisement
Rethinking Progression in Multiple Sclerosis
NeuroFrontiersRethinking Progression in Multiple Sclerosis
Charles Turck, PharmD, BCPS, BCCCP
Christopher Lock, MD
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstractsSwitching to Risdiplam Maintains Motor Gains in SMA Patients
Ryan Quigley
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiersWho’s Missing from Multiple Sclerosis Research?
Ashley Baker, MSN, PMHNP
Ruth Ann Marrie, MD, PhD
